GC Biopharma confirms safety of flu vaccine in phase 1 trial

The Korean company announced interim results of phase 1 clinical trial of patch-type vaccine

GC Biopharma Hwasun plant
GC Biopharma Hwasun plant
Jung-Eun Kim 1
2022-12-15 17:06:56 likesmile@hankyung.com
Bio & Pharma

South Korea's leading pharmaceutical company GC Biopharma Corp. said on Thursday that it has confirmed the safety and immunogenicity of the patch-type influenza vaccine MIMIX-Flu, which is under development jointly with Vaxess Technologies of the United States, in the interim clinical trial.

MIMIX-Flu is a product that combines GC Biopharma's flu vaccine antigen with Vaxess' patch-based subcutaneous drug delivery system, and the speed and time of drug delivery can be controlled by attaching a micro-needle to the patch to slowly release the drug.

The company's research team evaluated the safety and reactivity of the drug by having healthy adults between the ages of 18 and 39 wear the vaccine patch for 5 minutes.

As a result, side effects caused by the vaccine patch were less severe than conventional vaccines delivered by syringes, a company official said. He added that the seroconversion rate, which indicates the rate at which antibodies are produced by the vaccine, also exceeded the approval standards for flu vaccines stipulated by the US Food and Drug Administration.

The research team plans to continue follow-up observations for up to 180 days to evaluate the vaccine's long-term safety.

Write to Jung-Eun Kim at likesmile@hankyung.com
#Green Cross Corporation #Vaxess Technologies #MIMIX-Flu #patch-type influenza vaccine #gc biopharma patch

Green Cross' two Kosdaq-listed cell therapy arms to merge

Green Cross' two Kosdaq-listed cell therapy arms to merge

Green Cross's Hwasun factory in South Jeolla Province, South Korea South Korea's pharmaceutical group Green Cross Corp., or GC Pharma, will combine its two cell therapy developers listed on the junior Kosdaq market in efforts to scale up and sharpen its focus on the growing cell-based therapy m

Green Cross in talks with Russia to produce COVID-19 vaccine

Green Cross in talks with Russia to produce COVID-19 vaccine

Green Cross employees at Hwasun factory (Courtesy of Green Cross)  South Korea’s pharmaceutical company Green Cross Corporation (GC) is holding a series of close meetings on contract manufacturing of Russia’s COVID-19 vaccine CoviVac, according to industry sources on Mar. 17. C

GC Lab Cell, Artiva ink $1.9 bn deal with MSD

GC Lab Cell, Artiva ink $1.9 bn deal with MSD

South Korea-based biotechnology company Green Cross Lab Cell Corp. (GC Lab Cell) and its US-based subsidiary have inked a $1.9 billion deal to export the latest cell therapy platform technology to the global biopharmaceutical company Merck Sharp & Dohme Corp. (MSD), the company announced o
(* comment hide *}